Holen Sie sich die Stockscreener-App
86.74
0.36%
0.31
Handel nachbörslich:
86.74
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact? - TradingView
DexCom Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - jammulinksnews.com
Is DexCom Inc. a good long term investmentUnmatched profit growth - jammulinksnews.com
What drives DexCom Inc. stock priceMassive portfolio appreciation - jammulinksnews.com
What analysts say about DexCom Inc. stockHigh-yield portfolio picks - jammulinksnews.com
We Think DexCom (NASDAQ:DXCM) Can Manage Its Debt With Ease - simplywall.st
DexCom: Delivering Consistent Growth (NASDAQ:DXCM) - Seeking Alpha
Still Too Pricey? Dexcom’s Double-Digit Growth May Not Be Enough (DXCM) - Seeking Alpha
Are Medical Stocks Lagging DexCom (DXCM) This Year? - Yahoo Finance
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years - AOL.com
Dexcom recalls 19 models of glucose monitoring receivers - Modern Healthcare
Dexcom’s Recall of Certain CGM Receivers is Class I - Medical Product Outsourcing
Foletta sells Dexcom (DXCM) shares worth $234,216 - Investing.com Australia
Foletta sells Dexcom (DXCM) shares worth $234,216 By Investing.com - Investing.com Canada
FDA updates recall of certain Dexcom CGM speakers (DXCM) - Seeking Alpha
Assessing the Impact of Dexcom's Critical Device Recall on Its Market Position and Investor Sentiment - AInvest
Dexcom recalls glucose monitor receivers due to alert failure risk - Investing.com
Dexcom recalls glucose monitor receivers due to alert failure risk By Investing.com - Investing.com UK
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at - GuruFocus
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews - The News-Gazette
DexCom (DXCM) Target Price Raised by Mizuho Analyst | DXCM Stock News - GuruFocus
Analyst recommendations: Airbnb, Dexcom, Gitlab, AMD, Citigroup… - MarketScreener
Morgan Stanley Adjusts DexCom Price Target to $89 From $82, Maintains Equal Weight Rating - MarketScreener
Beyond The Numbers: 8 Analysts Discuss DexCom Stock - Benzinga
DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
When Should You Buy DexCom, Inc. (NASDAQ:DXCM)? - 富途牛牛
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes - Benzinga
DexCom, Inc. (DXCM) Stock Analysis: Evaluating a 18.25% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Ravens’ Mark Andrews leads first Dexcom U Signing Day Camp, inspiring young athletes with diabetes - WMAR 2 News Baltimore
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire
DexCom Is Doubling Down on Its ‘Mistake.’ Why It’s Time to Buy the Stock. - Barron's
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day - Investegate
What You Need to Know Ahead of DexCom’s Earnings Release - MSN
What You Need To Know Ahead Of DexCom’s Earnings Release - Barchart.com
Oppenheimer Reaffirms DexCom Buy Rating Amid HHS Wearables Push - MSN
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
3 Reasons Growth Investors Will Love DexCom (DXCM) - Yahoo Finance
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time. - BioSpace
0.62%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):